Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1358 • ACR Convergence 2025
Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
Masatsugu Komagamine¹, Sari Taguchi², Masataka Komagamine², Tetsuji Naka¹ and Minoru Fujimoto¹, ¹Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan, ²Komagamine Rheumatology and Orthopedic Clinic, Morioka, Japan
Background/Purpose: Methotrexate (MTX) is a foundational agent in the management of rheumatoid arthritis (RA). While oral MTX is widely prescribed, its subcutaneous (SC) formulation may…
Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Ko-Jen Li¹, Ting-Wei Chang², Tso-Ting Lai³, Jui-Hung Kao⁴, TING-YUAN LAN⁵, Tai-Ju Lee⁶, pei-Hsinq lai⁷, Shao-Yu Pai⁸, Chiehyu Shen⁹ and Song-Chou Hsieh¹⁰, ¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ³Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), ⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁶National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁷Taipei City Hospital, Taichung, Taiwan, ⁸National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
Abstract Number: 0566 • ACR Convergence 2025
Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
Astrid Goudot¹, Raphaël Hurtubise², Eugénie Robin³, Laurine Cadart⁴, Raghav Ramachandran⁵, Federica Re⁵, Tristan Pascart⁶, Cécile Philippoteaux⁷, René-Marc Flipo⁷, Laura Coates⁸ and Jean-Guillaume Letarouilly¹, ¹Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, Nord-Pas-de-Calais, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ³CH Valenciennes, Service de rhumatologie, Valenciennes, France, Valenciennes, France, ⁴Service de biostatistiques, CHU Lille, Lille, France, Lille, France, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ⁶GHICL, Hôpital Saint-Philibert, Service de rhumatologie, Lomme, France, Lomme, France, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Risk factors to identify patients who will develop a difficult-to-treat (D2T) psoriatic arthritis (PsA) are still lacking when initiating a first bDMARD. There are…
Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
MIDHUN SAKRAVARTHY JALANATHAN¹, Mehdi Ali Mirza¹, Vijaya prasanna Parimi², Seethalakshmi S¹ and Tejaswini Ramineni³, ¹ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 2273 • ACR Convergence 2025
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia

Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…
Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Alexia Zagouras¹, Sammy Pickell¹, Yuhan Liu¹, Ronald Witteles¹ and Matthew Charles Baker², ¹Stanford University, Stanford, CA, ²Stanford University, Menlo Park, CA
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
Abstract Number: 1357 • ACR Convergence 2025
Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
Jue Hou¹, Feiqing Huang², Gregory McDermott³, Jun Wen⁴, Mary Jeffway³, Ying Qi⁵, Yunqing Han³, Tianrun Cai⁶, Florence Bourgeois⁴, Katherine Liao⁷ and Tianxi Cai², ¹University of Minnesota, Minneapolis, MN, ²Harvard T.H. Chan School of Public Health, Boston, ³Brigham and Women's Hospital, Boston, ⁴Harvard Medical School, Boston, ⁵Brigham and Women’s Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: Validated rheumatoid arthritis (RA) disease activity measures such as the Disease Activity Score-28 (DAS28) are used in clinical trials but not universally recorded in…
Abstract Number: 1099 • ACR Convergence 2025
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Grace Haeun Lee¹, Gregory Challener², Janeth Yinh³, Jeffrey Sparks⁴, Kerry L. Reynolds⁵, Donald P. Lawrence⁵, Meghan J. Mooradian⁵, Ryan J. Sullivan⁵, Hyon K. Choi⁶ and Minna Kohler⁷, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) has been recommended [1-3] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), preferred due to its low immunosuppressive effect. However,…
Abstract Number: 0565 • ACR Convergence 2025
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Jensen Yeung³, Khalad Maliyar³, Siddhartha Sood³, Ahmet Bagit³, Muskaan Sachdeva³, Sahil Koppikar⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Lihi Eder⁶, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁴Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite advances in psoriatic arthritis (PsA) treatment, remission remains elusive for many patients. This has prompted growing interest in combining biologic and targeted synthetic…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
Abstract Number: 1350 • ACR Convergence 2025
Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) significantly impacts quality of life in multiple domains. This study aimed to evaluate the impact of initial biologic/targeted synthetic disease-modifying anti-rheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].